跳转到内容

抗雄激素:修订间差异

维基百科,自由的百科全书
删除的内容 添加的内容
Jimmy-bot留言 | 贡献
机器人: 尚未清空的已重定向分类(CAT:跨性别与医学CAT:跨性別與醫學
无编辑摘要
第23行: 第23行:


== 機轉 ==
== 機轉 ==
抗雄激素可分成[[類固醇]]類和非類固醇類
抗雄激素可按原理为雄性激素受體阻断剂、雄性激素合抑制剂,和[[抗促性腺激素]]三种


=== 阻断受体 ===
類固醇類抗雄激素對抗雄性激素,并且對第二徵也有影響。因為它有高脂性,所以可以擴散穿過[[細胞膜]]的[[雙磷脂層]],阻擋睪酮和[[双氢睾酮]](DHT)鍵結到受體上,進而影響基因表現活性。<ref name=" ">[http://healthandprostate.com/prostate-cancer/steroidal-antiandrogens "Steroidal Antiandrogens"] {{webarchive|url=https://web.archive.org/web/20120426051252/http://healthandprostate.com/prostate-cancer/steroidal-antiandrogens |date=2012-04-26 }},Health and Prostate. Retrieved 9 December 2011.</ref>


{| class="wikitable floatright"
非類固醇類抗雄激素,或稱為"純"抗雄激素,如{{tsl|en|nilutamide|尼鲁米特}}和[[氟他胺]],可以用于對抗雄性激素,且沒有類固醇的作用。其作用是阻斷雄性激素受體、抑制雄性激素生成,或者是兩者皆有。<ref name="Zouboulis CC, Rabe T.(March 2010). "Hormonal antiandrogens in acne treatment". Journal of the German Society of Dermatology 8 Suppl 1: S60–74.">[http://www.ncbi.nlm.nih.gov/pubmed/20482693 Zouboulis CC, Rabe T.(March 2010). "Hormonal antiandrogens in acne treatment". Journal of the German Society of Dermatology 8 Suppl 1: S60–74.],</ref>最常見的是抗[[雄性激素受體]]。直接鍵結在雄性激素受體上,使雄性激素無法作用,達到拮抗的效果。<ref name="Mowszowicz" />
|+ 雄激素和抗雄激素对{{abbr|AR|雄激素受体}}的结合<ref name="pmid2788775">{{cite journal | vauthors = Ayub M, Levell MJ | title = The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins | journal = J. Steroid Biochem. | volume = 33 | issue = 2 | pages = 251–5 | date = August 1989 | pmid = 2788775 | doi = 10.1016/0022-4731(89)90301-4 | url = }}</ref><ref name="pmid14751673">{{cite journal | vauthors = Yamasaki K, Sawaki M, Noda S, Muroi T, Takakura S, Mitoma H, Sakamoto S, Nakai M, Yakabe Y | title = Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals | journal = Toxicology | volume = 195 | issue = 2-3 | pages = 177–86 | year = 2004 | pmid = 14751673 | doi = 10.1016/j.tox.2003.09.012| url = }}</ref>
|-
! 物质!! {{abbrlink|RBA|相对结合亲和度}} (%)
|-
| {{tsl|en|Metribolone||}} || 100
|-
| [[双氢睾酮]] || 85
|-
| [[醋酸环丙孕酮]] || 7.8
|-
| [[螺内酯]] || 2.3
|-
| {{tsl|en|Bicalutamide|比卡鲁胺}} || 1.4
|-
| {{tsl|en|Nilutamide||}} || 0.9
|-
| {{tsl|en|Hydroxyflutamide||}} || 0.57
|-
| [[氟他胺]] || <0.0057
|}


阻断受体的可按结果分为[[類固醇]]類和非類固醇類两种。類固醇類抗雄激素与[[睾酮]]、[[孕酮]]等类固醇类似,由于其类固醇的结构经常会激活其他激素受体造成{{tsl|en|off-target activity|偏离目标的活}}<ref name="LemkeWilliams2012" />因為它有高脂性,所以可以擴散穿過[[細胞膜]]的[[雙磷脂層]],阻擋睪酮和[[双氢睾酮]](DHT)鍵結到受體上,進而影響基因表現活性。<ref name=" ">[http://healthandprostate.com/prostate-cancer/steroidal-antiandrogens "Steroidal Antiandrogens"] {{webarchive|url=https://web.archive.org/web/20120426051252/http://healthandprostate.com/prostate-cancer/steroidal-antiandrogens |date=2012-04-26 }},Health and Prostate. Retrieved 9 December 2011.</ref>[[比卡鲁胺]]和[[氟他胺]]这类非類固醇類抗雄激素则没有这类副作用,因此有时候也叫“纯”抗雄激素。<ref name="LemkeWilliams2012" />
每一個抗雄激素都有它特定機轉去抑制雄性激素的產生,如[[酮康唑]]不只跟[[睪酮|睾酮]]還有[[双氢睾酮]]競爭雄性激素受體,還會去抑制[[细胞色素P450]]和{{tsl|en|17,20-lyase|17,20-lyase}}的活性,而抑制了雄性激素的合成,導致腎上腺皮質生產的睾酮量下降。促性腺激素是一個可以改變雄性激素合成的腦垂體荷爾蒙,同樣會受到抗雄激素的影響。抗雄激素是經由減少促性腺激素釋放荷爾蒙受體而抑制了促性腺激素的分泌。促性腺激素釋放荷爾蒙受體的下降會使的促性腺激素釋放荷爾蒙(GnRH)無法跟受體有很好的結合率。GnRH是促使[[黄体生成素]]的[[泡膜细胞]]製造睾酮(間接的製造雌二醇)。所以,如果GnRH無法跟受體有好的鍵結,那麼就無法促進睾酮的生成。

== 抑制合成 ==
雄性激素合成抑制剂是抑制雄激素[[生物合成]]的[[酶抑制剂]]。<ref name="FiggChau2010">{{cite book|author1=William Figg|author2=Cindy H. Chau|author3=Eric J. Small|title=Drug Management of Prostate Cancer|url=https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA93|date=14 September 2010|publisher=Springer Science & Business Media|isbn=978-1-60327-829-4|pages=71–72,75,91–96}}</ref>雄激素的合成主要集中于[[性腺]]和[[肾上腺]],但在[[前列腺]]、[[毛囊]]等位置也有发生。如[[酮康唑]]不只跟[[睪酮|睾酮]]還有[[双氢睾酮]]競爭雄性激素受體,還會去抑制负责将[[孕烷]]类转换为雄激素的{{tsl|en|CYP17A1||}}的活性,从而抑制了雄性激素的合成,導致腎上腺皮質生產的睾酮量下降。<ref name="IIIBarbieri2013">{{cite book|author1=Jerome F. Strauss, III|author2=Robert L. Barbieri|title=Yen and Jaffe's Reproductive Endocrinology|url=https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA90|date=13 September 2013|publisher=Elsevier Health Sciences|isbn=978-1-4557-2758-2|pages=90–}}</ref>>由于CYP17A1还负责将[[盐皮质激素]]转换为[[糖皮质激素]],使用这类药物时经常需要配合[[强的松]]之类的糖皮质激素,用以防止[[肾上腺功能不足]]。<ref name="IIIBarbieri2013" /><ref name="FiggChau2010" />[[螺内酯]]也是通过抑制{{tsl|en|CYP17A1||}}发挥抗雄作用。

[[5α-还原酶抑制剂]]会抑制[[5α-还原酶]],从而抑制[[双氢睾酮]]的合成。<ref name = Flores>{{Cite journal |vauthors=Flores E, Bratoeff E, Cabeza M, Ramirez E, Quiroz A, Heuze I | title = Steroid 5alpha-reductase inhibitors | journal = Mini-Reviews in Medicinal Chemistry | volume = 3 | pages = 225–37 |date=May 2003 | pmid = 12570838 | issue = 3 | doi=10.2174/1389557033488196}}</ref>

== 抗促性腺激素 ==
促性腺激素,如[[黄体生成素]](LH)、[[促卵泡激素]](FSH),负责促使性腺制造性激素。抗促性腺激素会抑制[[垂体]]在[[GnRH]]作用下释放促性腺激素的功能。<ref name="FarmerWalker2012" />各种[[GnRH类似物]]都可以有效压制促性腺激素的产生,从而将男性的血浆雄激素含量降低95%。<ref name="FarmerWalker2012">{{cite book|author1=Peter B. Farmer|author2=John M. Walker|title=The Molecular Basis of Cancer|url=https://books.google.com/books?id=Bva8BAAAQBAJ&pg=PA232|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4684-7313-1|pages=232–}}</ref>由于[[下丘脑—垂体—性腺轴]]的[[负反馈]]调节,[[雌激素]]、[[孕激素]]也能有效降低促性腺激素的作用。<ref name="Brueggemeier2006" /><ref name="pmid10997774">{{cite journal |vauthors=de Lignières B, Silberstein S | title = Pharmacodynamics of oestrogens and progestogens | journal = Cephalalgia : an International Journal of Headache | volume = 20 | issue = 3 | pages = 200–7 |date=April 2000 | pmid = 10997774 | doi = 10.1046/j.1468-2982.2000.00042.x| url = http://cep.sagepub.com/cgi/pmidlookup?view=long&pmid=10997774}}</ref><ref name="pmid368741">{{cite journal | author = Neumann F | title = The physiological action of progesterone and the pharmacological effects of progestogens--a short review | journal = Postgraduate Medical Journal | volume = 54 Suppl 2 | issue = | pages = 11–24 | year = 1978 | pmid = 368741 | doi = | url = }}</ref>大剂量雌激素可以将雄激素降低到阉割水平,<ref name="pmid7000222">{{cite journal | vauthors = Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R | title = Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial | journal = Br J Urol | volume = 52 | issue = 3 | pages = 208–15 | year = 1980 | pmid = 7000222 | doi = 10.1111/j.1464-410x.1980.tb02961.x| url = }}</ref>大剂量孕激素也同样可以将男性的雄激素水平降低七到八成。<ref name="WeinKavoussi2011">{{cite book| first1 = Alan J. | last1 = Wein | first2 = Louis R. | last2 = Kavoussi | first3 = Andrew C. | last3 = Novick | first4 = Alan W. | last4 = Partin | first5 = Craig A. | last5 = Peters | name-list-format = vanc | title = Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set|url=https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2938|date=25 August 2011|publisher=Elsevier Health Sciences|isbn=978-1-4160-6911-9|pages=2938–}}</ref><ref name="pmid519881">{{cite journal | vauthors = Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF | title = Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men | journal = Clinical Endocrinology | volume = 11 | issue = 5 | pages = 497–504 | year = 1979 | pmid = 519881 | doi = 10.1111/j.1365-2265.1979.tb03102.x| url = }}</ref>


== 醫藥應用 ==
== 醫藥應用 ==

2018年7月27日 (五) 04:42的版本

抗雄激素
药物种类
Bicalutamide英语Bicalutamide, a nonsteroidal英语nonsteroidal antiandrogen and the most widely used androgen receptor antagonist in the treatment of prostate cancer.
用途Various
生物靶标Androgen receptor
ATC代码L02BB
外部链接
MeSHD000726

抗雄激素(anti-androgens),或稱為雄性激素拮抗劑(androgen antagonists)。於1960年代時被發現,藉由阻斷特定的受體而抑制雄性激素的作用。可以競爭細胞表面的接受器或是影響雄性激素的產生。[1]抗雄激素可用來治療一系列的疾病。在男性,抗雄激素經常用來治療前列腺癌引用错误:<ref>标签有衝突或無效的属性;对女性使用通常用來減少體內過多的雄性激素。抗雄激素對環境的影響已經受到高度的關注。許多的工業化學物質、殺蟲劑都有抗雄激素的作用。一些特定的植物也被發現會產生抗雄激素。環境中的抗雄激素對於生殖系統還在發育的小孩會有深遠的影響。

機轉

抗雄激素可按原理分为雄性激素受體阻断剂、雄性激素合成抑制剂,和抗促性腺激素三种。

阻断受体

雄激素和抗雄激素对AR的结合[2][3]
物质 RBA (%)
Metribolone英语Metribolone 100
双氢睾酮 85
醋酸环丙孕酮 7.8
螺内酯 2.3
比卡鲁胺英语Bicalutamide 1.4
Nilutamide英语Nilutamide 0.9
Hydroxyflutamide英语Hydroxyflutamide 0.57
氟他胺 <0.0057

阻断受体的可按结果分为類固醇類和非類固醇類两种。類固醇類抗雄激素与睾酮孕酮等类固醇类似,由于其类固醇的结构经常会激活其他激素受体,造成偏离目标的活性英语off-target activity[4]因為它有高脂性,所以可以擴散穿過細胞膜雙磷脂層,阻擋睪酮和双氢睾酮(DHT)鍵結到受體上,進而影響基因表現活性。[5]比卡鲁胺氟他胺这类非類固醇類抗雄激素则没有这类副作用,因此有时候也叫“纯”抗雄激素。[4]

抑制合成

雄性激素合成抑制剂是抑制雄激素生物合成酶抑制剂[6]雄激素的合成主要集中于性腺肾上腺,但在前列腺毛囊等位置也有发生。如酮康唑不只跟睾酮還有双氢睾酮競爭雄性激素受體,還會去抑制负责将孕烷类转换为雄激素的CYP17A1的活性,从而抑制了雄性激素的合成,導致腎上腺皮質生產的睾酮量下降。[7]>由于CYP17A1还负责将盐皮质激素转换为糖皮质激素,使用这类药物时经常需要配合强的松之类的糖皮质激素,用以防止肾上腺功能不足[7][6]螺内酯也是通过抑制CYP17A1发挥抗雄作用。

5α-还原酶抑制剂会抑制5α-还原酶,从而抑制双氢睾酮的合成。[8]

抗促性腺激素

促性腺激素,如黄体生成素(LH)、促卵泡激素(FSH),负责促使性腺制造性激素。抗促性腺激素会抑制垂体GnRH作用下释放促性腺激素的功能。[9]各种GnRH类似物都可以有效压制促性腺激素的产生,从而将男性的血浆雄激素含量降低95%。[9]由于下丘脑—垂体—性腺轴负反馈调节,雌激素孕激素也能有效降低促性腺激素的作用。[10][11][12]大剂量雌激素可以将雄激素降低到阉割水平,[13]大剂量孕激素也同样可以将男性的雄激素水平降低七到八成。[14][15]

醫藥應用

抗雄激素藥物可以用於一系列跟雄性激素有關的醫學問題。通常用於男性的前列腺癌良性前列腺增生症性慾亢進男性不孕症,還有正在進行激素替代疗法跨性别者Category:Hair loss medications英语Category:Hair loss medications Category:Hormonal antineoplastic drugs英语Category:Hormonal antineoplastic drugs Category:Prostate cancer英语Category:Prostate cancer

参见

参考文献

  1. ^ Mowszowicz I.(1989). "Antiandrogens. Mechanisms and paradoxical effects". Ann Endocrinol (Paris) 50 (3): 50 (3):189–99.
  2. ^ Ayub M, Levell MJ. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins. J. Steroid Biochem. August 1989, 33 (2): 251–5. PMID 2788775. doi:10.1016/0022-4731(89)90301-4. 
  3. ^ Yamasaki K, Sawaki M, Noda S, Muroi T, Takakura S, Mitoma H, Sakamoto S, Nakai M, Yakabe Y. Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004, 195 (2-3): 177–86. PMID 14751673. doi:10.1016/j.tox.2003.09.012. 
  4. ^ 4.0 4.1 引用错误:没有为名为LemkeWilliams2012的参考文献提供内容
  5. ^ "Steroidal Antiandrogens" 互联网档案馆存檔,存档日期2012-04-26.,Health and Prostate. Retrieved 9 December 2011.
  6. ^ 6.0 6.1 William Figg; Cindy H. Chau; Eric J. Small. Drug Management of Prostate Cancer. Springer Science & Business Media. 14 September 2010: 71–72,75,91–96. ISBN 978-1-60327-829-4. 
  7. ^ 7.0 7.1 Jerome F. Strauss, III; Robert L. Barbieri. Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. 13 September 2013: 90–. ISBN 978-1-4557-2758-2. 
  8. ^ Flores E, Bratoeff E, Cabeza M, Ramirez E, Quiroz A, Heuze I. Steroid 5alpha-reductase inhibitors. Mini-Reviews in Medicinal Chemistry. May 2003, 3 (3): 225–37. PMID 12570838. doi:10.2174/1389557033488196. 
  9. ^ 9.0 9.1 Peter B. Farmer; John M. Walker. The Molecular Basis of Cancer. Springer Science & Business Media. 6 December 2012: 232–. ISBN 978-1-4684-7313-1. 
  10. ^ 引用错误:没有为名为Brueggemeier2006的参考文献提供内容
  11. ^ de Lignières B, Silberstein S. Pharmacodynamics of oestrogens and progestogens. Cephalalgia : an International Journal of Headache. April 2000, 20 (3): 200–7. PMID 10997774. doi:10.1046/j.1468-2982.2000.00042.x. 
  12. ^ Neumann F. The physiological action of progesterone and the pharmacological effects of progestogens--a short review. Postgraduate Medical Journal. 1978,. 54 Suppl 2: 11–24. PMID 368741. 
  13. ^ Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol. 1980, 52 (3): 208–15. PMID 7000222. doi:10.1111/j.1464-410x.1980.tb02961.x. 
  14. ^ Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. 25 August 2011: 2938–. ISBN 978-1-4160-6911-9. 
  15. ^ Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF. Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men. Clinical Endocrinology. 1979, 11 (5): 497–504. PMID 519881. doi:10.1111/j.1365-2265.1979.tb03102.x.